allinckrodt has agreed to pay $35 million to settle charges of failing to report suspicious orders of controlled substances, the largest such deal involving a drug maker for such an infraction.

The deal also includes what authorities are calling a “groundbreaking parallel agreement” with the Drug Enforcement Agency, which will involve collecting and analyzing data from customers in order to identify suspicious sales.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.